 MONMOUTH JUNCTION, N.J., March 9, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record Total Revenue and CytoSorb sales in 2020, and record Product Gross Margins in Q4 2020. 